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Methods for single-cell genome and transcriptome
sequencing have contributed to our understanding
of cellular heterogeneity, whereas methods for
single-cell epigenomics are much less estab-
lished. Here, we describe a whole-genome bisulfite
sequencing (WGBS) assay that enables DNAmethyl-
ationmapping in very small cell populations (mWGBS)
and single cells (scWGBS). Our assay is optimized
for profiling many samples at low coverage, and we
describe a bioinformatic method that analyzes col-
lections of single-cell methylomes to infer cell-state
dynamics. Using these technological advances, we
studied epigenomic cell-state dynamics in three in
vitro models of cellular differentiation and pluripo-
tency, where we observed characteristic patterns of
epigenome remodeling and cell-to-cell heterogene-
ity. The described method enables single-cell anal-
ysis of DNAmethylation in a broad range of biological
systems, including embryonic development, stem
cell differentiation, and cancer. It can also be used
to establish composite methylomes that account for
cell-to-cell heterogeneity in complex tissue samples.INTRODUCTION
Cellular differentiation is accompanied by widespread epige-
nome remodeling. Changes in epigenetic marks such as DNA
methylation and histone modifications are being studied with
genome-wide assays (Bernstein et al., 2007; Rivera and Ren,
2013), which have advanced our understanding of epigenomic
cell states. However, current assays typically require thousands
to millions of cells per experiment, making it difficult to study rare
cell populations and cell-to-cell heterogeneity. Recent advances
in single-cell RNA sequencing demonstrate the value of a higher
resolution view (Sandberg, 2014) and suggest that methods for1386 Cell Reports 10, 1386–1397, March 3, 2015 ª2015 The Authorssingle-cell epigenome mapping could promote our understand-
ing of epigenetic regulation in development and disease.
Whole-genome bisulfite sequencing (WGBS) is the current
gold standard for DNA methylation mapping (Cokus et al.,
2008; Lister et al., 2008), and it provides coverage for more
than 90% of the approximately 28.7 million CpGs in the human
genome. The standard WGBS protocol requires micrograms of
input DNA, but research is continuing to push this number lower.
For example, a tagmentation WGBS protocol reduces the DNA
requirements to 20 ng, albeit at the cost of reduced genome-
wide coverage (Adey and Shendure, 2012; Wang et al., 2013).
As a cost-effective alternative to WGBS, reduced representation
bisulfite sequencing (RRBS) yields accurate DNA methylation
maps covering 1–2 million CpGs from 30 ng of human DNA
(Bock et al., 2010; Gu et al., 2010). RRBS has also been applied
to populations of about 100 cells from mouse embryos and oo-
cytes (Smallwood et al., 2011; Smith et al., 2012), yielding data
for 1–2 million CpGs out of the approximately 21.9 million
CpGs in the mouse genome.
Moving to single-cell analysis of DNA methylation is techni-
cally challenging because bisulfite treatment causes extensive
DNA damage in the form of nicks, fragmentation, and abasic
sites. To overcome this issue, Lorthongpanich et al. (2013)
avoided bisulfite treatment altogether and combined methyl-
ation-specific restriction enzymes with qPCR, which allowed
them to measure DNA methylation in single cells at a few dozen
candidate CpGs. Guo et al. (2013) demonstrated genome-scale
RRBS in single cells with coverage of 0.5–1 million CpGs. And
most recently, Smallwood et al. (2014) extended the post-bisul-
fite adaptor tagging protocol (Miura et al., 2012) with a whole-
genome pre-amplification step, yielding coverage of several
million CpGs from single mouse cells.
Here, we describe a WGBS protocol optimized for high-
throughput profiling of many single cells. We validated this pro-
tocol in both mouse and human cells, and produced the first
single-cell methylomes of human cells. To effectively analyze
and interpret these data, we developed a bioinformatic method
that infers epigenomic cell-state dynamics from low-coverage
methylome data. We sequenced over 250 samples in three
in vitro models of cellular differentiation. Our results provide a
single-cell perspective on epigenomic cell-state dynamics in
pluripotent and differentiating cells, and a broadly applicable
method for studying DNA methylation both in single cells
(scWGBS) and in very small cell populations (mWGBS).
RESULTS
Low-Input and Single-Cell WGBS
In most WGBS protocols, bisulfite treatment is performed after
the sequencing adapters have been ligated, which makes
the workflow compatible with standard methods for double-
stranded adaptor ligation. Unfortunately, these protocols suffer
from high DNA loss because any induced DNA damage between
the two ligated adapters can interfere with PCR amplification.
We therefore focused our optimizations on an existing protocol
that uses post-bisulfite adaptor ligation on 50 ng of input DNA,
and we found that we could obtain close to optimal methylome
data from 6 ng of input DNA (5.8% PCR duplicate read rate, as
compared with 1.9% for 50 ng).
To explore the feasibility of sequencing single cells using our
optimized protocol, we established a fluorescence-activated
cell sorting (FACS)-based workflow that sorts defined numbers
and combinations of human and/or mouse cells into single wells
of 96-well microtiter plates. The cells can then be lysed, bisulfite
treated, and prepared for sequencing (Figure 1A). Importantly,
the whole process of library preparation following bisulfite treat-
ment and cleanup is performed in a single tube, which minimizes
DNA loss and reduces contamination risk. We validated the ac-
curacy of our workflow in several ways. First, FACS plots
confirmed that we could distinguish single cells from rare cell
doublets in individual wells of 96-well plates (Figures S1A and
S1B). Second, we validated the sensitivity and specificity of
the sorting by placing a single mouse embryonic stem cell
(ESC) into each well of a 96-well plate. When we counted the
number of colonies after 10 days, we observed that 78% of the
wells contained exactly one colony and no well contained
more than a single ESC colony (Figure S1C). Third, we seeded
single mouse hematopoietic 32D cells for clonal expansion and
counted the number of cells at days 8, 9, 10, and 11. Extrapola-
tion showed that the observed numbers were consistent with
exponential growth starting from a single cell (Figure S1D).
Fourth, we performed clonal expansion of human leukemic
K562 cells starting from 1, 2, 4, and 8 cells, and we observed
2-fold differences in cell number at day 21, reflecting the 2-fold
differences in the number of seeded cells (Figure S1E).
Having validated our ability to accurately sort single cells, we
tested the mWGBS protocol for starting amounts of 500, 50,
20, 10, 4, and 1 cell(s), using no more than 18 PCR cycles for
library amplification. Data quality was acceptable all the way
down to single cells, although there was a visible and progres-
sive deterioration in genomic coverage (Figures 1B and S1F).
Importantly, multidimensional scaling (MDS) analysis grouped
all samples according to cell type rather than cell number (Fig-
ure 1C). Even the one-cell samples clustered with the positive
control samples that used 50 ng input DNA, and theywere clearly
distinguishable from all negative controls (which included li-
braries prepared from zero cells as well as mouse libraries with
reads aligned to the human genome). These observations indi-Cecate that our protocol can provide accurate DNA methylation
measurements all the way down to single cells.
For additional quality control, in most experiments we sorted
one human cell together with four mouse cells (or vice versa)
into the same well and performed library preparation on these
cell pools. By aligning to both genomes, we could compare the
ratio of aligned reads with the ratio of sorted cells and discard
samples in which the single cell was lost between sorting and
library preparation. Most libraries were well within the expected
range (examples are shown in Figure 1D), which provides further
validation of the accuracy and robustness of our workflow.
Moreover, by comparing cell-type-specific signatures of copy-
number variation, we could also confirm that the analyses were
not confounded by contaminating DNA (Figure 2A). Finally, to
monitor the efficiency of bisulfite conversion, we included meth-
ylated and unmethylated oligonucleotides as spike-in controls in
most of our libraries, and we observed highly consistent bisulfite
conversion rates (Figure 2B).
We prepared and sequenced more than 250 individual
samples using the described protocol and workflow. Of these,
more than 80% passed all quality-control filtering and were
included in our analysis, resulting in 82 single-cell methylomes,
89 four-cell methylomes, and 53 other optimization and qual-
ity-control samples (Table S1). We sequenced most samples
at low coverage. In humans, a median of 4.6 million reads for
the one-cell samples and 13.7 million for the four-cell samples
resulted in a median CpG coverage of 1.4 million for one-cell
samples and 3.7 million for four cell samples (Figures 2C and
S2; Table S2).
Deeper sequencing of a single library consisting of one mouse
cell and four human cells increased the CpG coverage by 86%
(mouse one-cell) and 62% (human four-cell), but at the cost of
high PCR duplicate rates. We observed much more pronounced
increases in genome-wide CpG coverage when we combined
data from several dozen low-coverage one-cell or four-cell sam-
ples into a single composite methylome (Figures 2D, 2E, and
S3). This approach profits from the low amplification bias of
our protocol (Figure S2), and more than 90% of CpGs in the hu-
man and mouse genomes can be covered when a few dozen
one-cell or four-cell samples are combined (Figures 2D and
2E). We thus concluded that it is more cost-effective to
sequence many one-cell and four-cell samples at low coverage
rather than sequencing relatively few of these samples to satu-
ration, and we show below that relatively shallow sequencing
can be sufficient for analyzing epigenomic cell-state dynamics
(cf. Figures 4, 5, and 6). This conclusion is consistent with recent
data from single-cell transcriptomics, where low-coverage
sequencing of many samples has become a preferred strategy
for reconstructing cellular lineages (Jaitin et al., 2014; Pollen
et al., 2014).
Analysis of Single-Cell Methylome Dynamics in Human
Hematopoietic Cell Lines
Having established a scWGBS workflow that is sufficiently
fast, robust, and cost-effective for processing a larger num-
ber of samples, we applied our method to two models of
epigenome remodeling and cellular differentiation in human
hematopoietic cell lines (Figure 3A). MDS analysis of the globalll Reports 10, 1386–1397, March 3, 2015 ª2015 The Authors 1387
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Figure 1. A Workflow for Single-Cell Methylome Sequencing
(A) Overview of the workflow. Defined numbers of human and mouse cells are sorted by FACS and the DNA is bisulfite converted directly on lysed cells, followed
by single-strand library preparation and paired-end sequencing.
(B) DNA methylation profiles for four representative genomic regions, plotting the mean DNA methylation levels for windows of 20 kb. The y axis follows the DNA
input titration in KBM7 cells (upper panel) and the cell-based titration in K562 cells (lower panel).
(C) Multidimensional scaling (MDS) analysis for average DNA methylation levels of 1-kb tiling regions in DNA-based and cell-based titration samples.
(D) Expected and observed alignment rates for representative samples that passed quality-control filtering. The yellow zones indicate the range of expected
values for the ratio of reads aligned to the human and mouse genomes.
See also Figure S1 and Table S1.similarity among these one-cell, four-cell, and bulk samples
showed consistent grouping by cell line (Figure 3B), indicating
that the DNA methylation differences between cell lines were
stronger than both the variation among single cells (Figure 3B)1388 Cell Reports 10, 1386–1397, March 3, 2015 ª2015 The Authorsand the treatment effect in each of the two models (Figures 3C
and 3D).
Our first in vitro model was the K562 erythroleukemia-derived
cell line treated with azacytidine, an epigenetic drug that is
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Figure 2. Performance Evaluation of Single-Cell Methylome Sequencing
(A) Strip charts demonstrating concordance between the expected copy-number aberrations in HL60 and K562 cancer cell lines (based on published data) and
the observed sequencing coverage.
(B) Estimated rates of bisulfite over-conversion and under-conversion based on methylated and unmethylated oligonucleotides used as spike-in controls.
(C) Scatterplot illustrating the relationship between CpG coverage and sequencing depth for individual one-cell and four-cell human samples. Marginal distri-
butions are plotted as hash marks (rugs) along the axes (see Figure S2 for additional details).
(D) Saturation plot illustrating the relationship betweenCpG coverage and sequencing depth when combiningmultiple human samples. Plots show the number of
unique CpGs covered (y axis) as a function of aligned reads (x axis). Points are averages across ten iterations adding the individual samples in random order, and
the corresponding SDs of CpG coverage are plotted as vertical error bars.
(E) Same as (D) but for mouse samples.
See also Figures S2 and S3 and Table S2.routinely used in leukemia therapy (Issa and Kantarjian, 2009).
Azacytidine depletes DNA methyltransferases, thereby causing
widespread reduction in DNA methylation (De Carvalho et al.,
2012). We sequenced 31 one-cell and four-cell samples com-
prising three time points (untreated, 48 hr, and 96 hr) and
observed that the samples generally grouped by treatment
status (Figure 3C), although there were two treated one-cell
samples that clustered with the untreated samples, possibly
because these two cells had not divided in the hours after azacy-
tidine treatment. We also observed the expected reduction
in global DNA methylation levels in all but these two cells
(Figure 3E).
Our second in vitro model was the HL60 cell line, which can be
differentiated into monocyte-like cells by treatment with vitamin
D3 (Birnie, 1988; Stegmaier et al., 2004). HL60 cells are not
known to undergo widespread epigenome remodeling upon
vitamin D3 treatment, and the observed morphological changes
(Figure 3A) may occur in the absence of major changes in DNA
methylation. We analyzed 38 one-cell and four-cell samplesCethat were untreated or treated with vitamin D3 for 48 hr, 120 hr,
and 14 days. The one-cell and four-cell samples grouped
together according to treatment time (Figure 3D), with distinct
directions for the 120-hr and 14-day treatment periods. How-
ever, the separation was less clear than in the K562 experiment,
and we did not observe any significant changes in global DNA
methylation levels (Figure 3E). Overall, the DNA methylation
changes that accompanied induced differentiation in HL60 cells
were much more subtle than the azacytidine-induced global de-
methylation of K562 cells.
In both models we also explored whether there were any
changes in cell-to-cell variability upon treatment (Figure 3F). To
that end, we measured the pairwise Euclidian distances of
samples within a treatment group, and we indeed observed an
initial increase of cell-to-cell variability upon induction of treat-
ment, followed by a reduction of variability at a later time point.
This observation is consistent with the hypothesis that external
stimuli such as azacytidine and vitamin D3 initially boost epige-
nome variability because cells respond individually to treatment,ll Reports 10, 1386–1397, March 3, 2015 ª2015 The Authors 1389
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Figure 3. Single-Cell DNA Methylation Dynamics in Drug-Treated and Differentiation-Induced Cell Lines
(A) Bright-field microscopy images of two in vitro models for changes in cell state: K562 cells treated with azacytidine, and HL60 cells treated with vitamin D3.
(B) MDS analysis for average DNA methylation levels of 1-kb tiling regions in human hematopoietic cell line samples.
(C) MDS analysis for K562 cells treated with azacytidine.
(D) MDS analysis for HL60 cells treated with vitamin D3.
(E) Strip charts showing global DNA methylation levels for each sample.
(F) Analysis of pairwise Euclidian distances between individual K562 and HL60 samples.whereas the variability decreases again when the cells reach
their new cell state.
Bioinformatic Method for Inferring Epigenomic Cell-
State Dynamics from Single-Cell DNA Methylation Data
Analyzing single-cell methylome data is bioinformatically
challenging because the DNA methylation measurements are
sparse and discrete. In our initial analysis of global trends1390 Cell Reports 10, 1386–1397, March 3, 2015 ª2015 The Authorsin single-cell methylome data (Figure 3), we addressed this
issue by averaging DNA methylation levels across 1-kb
genomic regions. But more sophisticated methods are needed
to obtain insights into the concrete biological processes in
such data sets. We thus developed a dedicated bioinformatic
method for analyzing single-cell and low-coverage DNA
methylation data and inferring epigenomic cell-state dynamics
(Figure 4 and Experimental Procedures).
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Figure 4. A Bioinformatic Method for Analyzing Low-Coverage and Single-Cell Methylome Data
(A) Aggregation of single-cell DNA methylation data using several thousand biologically defined genomic region sets obtained from public databases.
(B) Scatterplots comparing individual one-cell and four-cell samples against the average calculated across all untreated control samples. The dots represent
mean DNA methylation levels across all regions in a given set. Two representative control samples (top row) and two representative 96-hr azacytidine samples
(bottom row) are shown.
(C) Correction for systematic global effects among the observed DNA methylation differences. After normalizing to control methylation, a linear model is fitted to
model change in DNAmethylation level of one individual sample while controlling for the effects of CpG content andDNAmethylation level in the untreated control
samples.
(D) Scatterplots of the DNA methylation change observed in individual samples plotted against the mean DNA methylation levels among all untreated samples.
Each dot represents a region set.
(E) By comparing across individual treated samples, one can identify region sets that show significantly higher (left) or lower (right) DNA methylation levels than
expected based on the linear model.
(F) Positive and negative residuals for region sets with significantly higher or lower DNA methylation levels in comparison to the prediction of the linear model in
K562 cells. Alternating black and gray coloring is for visualization purposes only. Region sets with consistently positive residuals across samples (left) comprise
genomic regions for which DNA methylation is decreasing less quickly with treatment than expected based on the initial DNA methylation state. Negative
residuals (right) indicate regions that lose methylation more quickly than expected. The full list of region types is available in Figure S4.
(G) Scatterplot derived by averaging the positive (y axis) and negative (x axis) residuals for each individual sample based on the region sets that are significantly
different from expectation.
(H) Scatterplot comparing the 96-hr samples and the untreated controls, with 48-hr samples superimposed.
See also Figure S4.Briefly, our method measures the degree to which individual
one-cell or four-cell samples differ from a set of control samples
in terms of average DNA methylation levels across all regions
of a given type (such as chromatin binding peaks for p300
or cell-type-specific DNase-hypersensitive sites). Small DNA
methylation differences at cell-type-specific transcription factor
binding sites have been shown to correlate with cell-type-spe-
cific enhancer activity (Bock et al., 2012; Feldmann et al.,
2013; Stadler et al., 2011), and combining data across thou-
sands of similar functional elements provides sufficient statistical
power to identify small changes in DNA methylation among sub-
sets of such regions. The excellent catalogs of gene-regulatory
regions that are now available for the human and mouse ge-
nomes provide the basis for extracting biologically relevant
signals from our single-cell experiments.CeWe illustrate our method by analyzing the azacytidine treat-
ment methylomes in more detail (Figure 4). We collected 2,768
experimentally defined region sets from ENCODE and other
sources (ENCODE Project Consortium, 2012; Liu et al., 2011;
Sheffield et al., 2013), comprising cell-type-specific DNase-hy-
persensitive sites, regions marked by various histone modi-
fications, transcription factor binding sites, and other types of
regulatory regions. For each sample and each region set, we
calculated the sample’s mean DNA methylation value across
all regions of the given region set, resulting in amatrix of samples
and region types (Figure 4A). This matrix can be used to visualize
the differences of individual samples relative to a defined group
of control samples (in this case, all untreated K562 samples).
As expected, there were no systematic differences for individ-
ual control samples compared with the average of all controlll Reports 10, 1386–1397, March 3, 2015 ª2015 The Authors 1391
samples, but we observed a clear reduction in global DNA
methylation levels for the azacytidine-treated samples (Fig-
ure 4B, red arrows). Furthermore, there was higher variability
among the one-cell samples compared with the four-cell sam-
ples (blue arrows), which disappeared when we combined four
one-cell samples into a composite four-cell sample (Figure S4A).
An aggregate analysis of genomic region sets confers suffi-
cient statistical power to identify types of regions that lose
DNA methylation faster or slower than average, which can help
identify relevant regulatory mechanisms (Figures 4C and 4D).
In this analysis, we corrected for two systematic effects that
would otherwise dominate the comparison. First, region sets
with relatively high DNA methylation levels in the untreated sam-
ples were more likely to lose methylation in response to treat-
ment than region sets that were already unmethylated in the
untreated samples (as indicated by the trend line and red arrows
in Figure 4D). Second, epigenome variability tends to follow
different patterns in CpG-rich regions compared with CpG-
poor regions (Bock et al., 2008). We corrected for both effects
by fitting a linear model for each sample and predicting the ex-
pected DNA methylation differences for each region type given
the DNA methylation level among the control samples and the
CpG content (Figure 4D). By subtracting the expected DNA
methylation differences from the observed ones (i.e., by calcu-
lating the residuals for the linear model), we identified region
types that were more methylated (or less methylated) than one
would expect if azacytidine-induced DNA demethylation were
entirely unspecific. We then identified region types that were
consistently different from the expected value across several in-
dividual cells (Figure 4E).
Region types with a consistently positive residual (i.e., those
that lose DNA methylation relatively slowly upon azacytidine
treatment) were associated with repressive chromatin in K562
cells, whereas regions with consistent negative residuals (i.e.,
those that lose DNA methylation relatively quickly) comprised
lineage-specific enhancer elements and transcription factor
binding sites (Figure 4F). This trend was visible not only for the
96-hr samples that were used to define the difference but also
for the 48-hr samples (Figure S4B). Finally, we used all region
types with statistically significant residuals to visualize single-
cell trends (Figure 4G). To that end, we plotted the samples ac-
cording to their average DNAmethylation levels across all region
types with significantly positive residuals (y axis in Figure 4H)
versus the average DNA methylation levels across all region
types with significantly negative residuals (x axis in Figure 4H).
The 48-hr samples fell clearly between the untreated samples
and the 96-hr samples, supporting our conclusion that azacyti-
dine treatment induces epigenomic changes that are progres-
sive and robustly detectable among single cells (with the excep-
tion of the two outliers that were already identified in Figure 3).
We also applied this bioinformatic method to the HL60 sam-
ples, which grouped less clearly in the initial MDS analysis (Fig-
ure 3D) and did not exhibit global changes in DNA methylation
levels (Figure 3E). When we compared untreated samples with
cells that had been treated with vitamin D3 for 14 days, we found
that a small number of region types differed significantly from the
linear model prediction (Figure S4C), allowing us to derive a line-
age plot for HL60 differentiation (Figure S4D). Among the region1392 Cell Reports 10, 1386–1397, March 3, 2015 ª2015 The Authorstypes with elevated DNA methylation levels upon differentiation
were ESC enhancer elements, and among those with reduced
DNA methylation were DNase-hypersensitive sites specific to
blood cell development. These results suggest that differentia-
tion processes without global changes in DNA methylation
can exhibit localized patterns of DNA methylation change that
are progressive, consistent among single cells, and detectable
with our method.
Dissecting Mouse ESC Differentiation and Pluripotency
through Single-Cell DNA Methylation Mapping
To test our method in an additional biological system, we applied
scWGBS to mouse ESCs cultured in feeder-free serum condi-
tions with leukemia inhibitory factor (LIF) and upon induction of
three different stimuli (Figure 5A). First, we induced conversion
to naive pluripotency by moving the cells into 2i medium. Sec-
ond, we induced embryoid body (EB) formation by withdrawing
LIF, causing undirected differentiation. Third, we treated ESCs
with all-trans retinoic acid (ATRA) to induce differentiation in a
more directed way.
Among 81 methylomes derived from one-cell and four-cell
samples, we observed substantial changes in global DNA
methylation levels (Figure 5B). When exposed to 2i medium,
most ESCs were significantly demethylated, consistent with pre-
vious observations on bulk samples (Habibi et al., 2013). Global
DNAmethylation levels also decreased after sustained treatment
with ATRA (day 14), whereas EB differentiation led to increased
DNA methylation levels. MDS analysis of all samples identified
one dominant cluster comprising untreated and early-treatment
cells, and three treatment-specific clusters branching out
in different directions (Figure 5C). These genome-wide trends
were also visible at individual loci (Figures 5D and S5). Further-
more, we observed differences between one-cell and four-cell
samples only for the 120-hr time point, and these samples
were collected on different days in different experiments, sug-
gesting that the speed of DNA demethylation differed between
these experiments (Figures 5B and 5C).
For an in-depth analysis, we applied the bioinformatic method
outlined in Figure 4 to the mouse ESC methylomes. When we
compared untreated samples against all 120-hr 2i samples, we
observed consistent changes in DNA methylation for several
types of genomic regions (Figure 6A). First, the region set that
wasmost significantly protected from global demethylation con-
sisted of imprinted gene-regulatory regions, indicating that ESCs
faithfully maintain genomic imprints in 2i medium despite very
low levels of DNA methyltransferase activity. Second, region
sets associated with repressive chromatin lost DNA methylation
more slowly than expected, whereas enhancer regions of essen-
tially any lineage lost DNA methylation faster. Third, the region
sets that lost DNA methylation the fastest overlapped heavily
with ESC-specific enhancers, suggesting that their change in
DNA methylation levels may be directly driven by the increased
activity of the pluripotency regulatory network in 2i medium.
These trends were visible not only in the 120-hr samples used
to define the difference but also progressively at the 96-hr time
point (Figure S6).
When we investigated the DNAmethylation dynamics in differ-
entiating cells, we observe strikingly anticorrelated patterns
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Figure 5. Single-Cell Analysis of Epigenome Remodeling in Pluripotent and Differentiating ESCs
(A) Bright-field microscopy images of mouse ESCs (CCE cell line) cultured in feeder-free serum conditions with LIF (center), after 120 hr in 2i medium (left), and
after differentiation induced by ATRA treatment (top right) or by embryoid body (EB) formation (bottom right).
(B) Strip charts showing global DNA methylation levels for each sample and time point.
(C) MDS analysis for average DNA methylation levels of 1-kb tiling regions in mouse ESC derived samples.
(D) DNAmethylation profiles for genomic regions associated with two neural differentiation genes, plotting themean DNAmethylation levels for windows of 20 kb.
See also Figure S5.(Figures 6B and S6). Region types that lost DNA methylation
most quickly in 2i medium rapidly gained DNA methylation
upon EB formation or ATRA treatment, whereas region types
that were most protected from DNA methylation loss under
2i conditions had comparatively low DNA methylation levels
among the differentiating cells. Only imprinted loci were pro-
tected from loss of DNA methylation in either case and in most
samples, suggesting that the epigenetic machinery that main-
tains imprints is able to withstand the changes associated with
pluripotency and differentiation in mouse ESCs.
Finally, we plotted all samples according to the average DNA
methylation levels among the region types that were identified
as significantly different (Figure 6C). The resulting lineage plot
organizes all samples along two anticorrelated dimensions of
positive residuals (y axis, primarily repressed chromatin) and
negative residuals (x axis, primarily open chromatin). It accu-
rately reflects the expected cell states of most of the one-cell
and four-cell samples, and is robust enough to compensate for
the variable speed of demethylation that we observed among
the different 120-hr 2i experiments (cf. Figure 5C). AlthoughCethis plot was created solely on the basis of differences between
120-hr 2i cells and serum-cultured cells, it logically places the
ATRA-induced and EB differentiating cells in the opposite direc-
tion. This is not merely a reflection of global changes in DNA
methylation, as the ATRA and EB differentiation time courses
induce opposite global changes; instead, this observation indi-
cates that our method is able to robustly identify sets of genomic
regions from the data that exhibit inverse trends among naive
pluripotent and differentiating mouse ESCs.
DISCUSSION
Here we have described an integrated approach for single-cell
methylome sequencing and bioinformatic inference of epige-
nomic cell-state dynamics, and demonstrated its utility in three
in vitro models of drug-induced epigenome remodeling, cellular
differentiation, and pluripotency. Our workflow includes an opti-
mized protocol for low-input and single-cell bisulfite sequencing
that is complementary to two recently described protocols:
single-cell RRBS (scRRBS; Guo et al., 2013) and single-cellll Reports 10, 1386–1397, March 3, 2015 ª2015 The Authors 1393
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Figure 6. Identification of KeyRegulatory Regions and Inference of Epigenomic Cell-State Dynamics for Pluripotent andDifferentiating ESCs
(A) Residual plot identifying region types with significant differences in DNAmethylation between ESCs cultured in 2i medium for 120 hr and untreated samples as
controls. The full list is available in Figure S6.
(B) Residual plot based on the same regions as in (A), but showing 7-day EB samples compared with untreated samples.
(C) Lineage plot displaying all mouse ESC-derived samples according to the sum of the significant residuals between ESCs cultured in 2i medium for 120 hr and
the untreated control samples.
See also Figure S6.post-bisulfite adaptor tagging (scPBAT; Smallwood et al., 2014)
(Table S2). Compared with the scRRBS protocol’s focus on CpG
islands (Guo et al., 2013), our protocol is relatively unbiased
and provides cumulative coverage for more than 90% of CpGs
in the human and mouse genomes when combining data across
experiments (Figures 2D, 2E, and S3). And in contrast to the
recently published scPBAT protocol (Smallwood et al., 2014),
our protocol does not require any pre-amplification, which offers
a number of concrete advantages (e.g., lower reagent cost, less
hands-on time, reduced amplification bias, no confounding of
strandedness, correct assignment of paired-end fragments,
and accurate measurement of PCR duplicates) but comes at
the cost of somewhat lower library complexity (Figure S3). We
conclude that scWGBS is the method of choice for analyzing
large numbers of single cells at low sequencing coverage,
scRRBS is useful for comparing CpG islands across single cells,
and scPBAT is best suited for deeply sequencing single cells
with maximum coverage.
We also developed a bioinformatic method for inferring epige-
nomic cell-statedynamics fromsparsemethylomedata. Because
DNAmethylation patterns at regulatory elementsof the same type
tend to respond similarly to changes in epigenomic cell states, our
method gains statistical power by combining data on the level of
genomic region sets. We tailored the method specifically to sin-
gle-cell methylome data, but it could also be useful for analyzing
low-coverage WGBS data from large patient cohorts. The three
presented case studies demonstrate that our method is able to1394 Cell Reports 10, 1386–1397, March 3, 2015 ª2015 The Authorsplace single cells on biologically interpretable time-course trajec-
tories, even in caseswhere changes in DNAmethylation are locus
specific andnon-linear, as illustrated by the humanHL60differen-
tiation and mouse ESC differentiation data.
We anticipate that single-cell methylome sequencing will
be useful for a broad range of applications, such as epigenome
analysis of heterogeneous organs (Maze et al., 2014) and
research on epigenetic drug resistance (Bock and Lengauer,
2012). Because DNA methylation is correlated with histone
modifications and chromatin states, it may become possible
to use DNA methylation as a surrogate for inferring broader
changes in epigenomic cell states. Furthermore, by sequencing
and combining dozens of low-input methylomes from the same
sample (e.g., one-cell, four-cell, or 20-cell pools), itwill bepossible
to create composite methylomes that provide excellent genome-
wide coverage based on relatively few cells and include an
inherent assessment of variation. Essentially, composite methyl-
omes redefine the concept of reference epigenome corridors
(Bock et al., 2011) in the context of individual samples, thus
providing a new type of reference methylome map that can ac-
count for tissue heterogeneity and cell-to-cell variation.EXPERIMENTAL PROCEDURES
Cell Culture and FACS
K562 and HL60 cells were cultured in RPMI medium supplemented with 10%
fetal calf serum (FCS) and antibiotics. KBM7 cells were cultured in Iscove’s
modified Dulbecco’s medium (IMDM) and supplemented with 10% FCS and
antibiotics (Bu¨rckstu¨mmer et al., 2013). Mouse ESCs of the CCE cell line
were cultured in feeder-free growth conditions using DMEM with the addition
of 15% FCS, 2-mercaptoethanol, sodium pyruvate, glutamine, and LIF. 32D
cells were cultured in RPMI medium supplemented with 10% FCS, 5 ng/ml
mIL3 (eBiosciences, 34-8031-82), and antibiotics. Cell growth and viability
were monitored using a CASY cell counter (Roche Diagnostics). FACS was
performed using the MoFlo Astrios cell sorter (Beckman Coulter). Prior to
FACS, the cells were pushed through a 40 mM cell strainer to ensure the sep-
aration of possible aggregates into single cells.
Perturbation Experiments
K562 cells were treated with 5-azacytidine (Toronto Research Chemicals, cat-
alog number A796000) in a final concentration of 1 mM to induce demethyla-
tion. HL60 cells were treated with 1a,25-dihydroxyvitamin D3 (Sigma-Aldrich,
D1530) in a final concentration of 10 nM to induce differentiation (Ostrem et al.,
1987). Naive pluripotency of mouse ESCs was induced by culturing the cells in
ESGRO-2i medium (Merck Millipore, SF016) with the addition of 1% FCS. Dif-
ferentiation of mouse ESCs was induced by treating the cells with ATRA
(Sigma-Aldrich, R2625) in a final concentration of 0.3 mM every third day along
with complete LIF-free medium exchange. EB formation from mouse ESCs
was induced by hanging-drop culture for 5 days, followed by 9 days on gelati-
nized dishes.
Whole Genome Bisulfite Sequencing
For the positive control samples (which started from 50 ng extracted DNA) and
the DNA input titration, DNA was extracted using theWizard SV Genomic DNA
Purification System (Promega, A2360). Bisulfite conversion was performed
using the EZ DNA Methylation-Direct Kit (Zymo Research, D5020) according
to the manufacturer’s protocol, with the modification of eluting the DNA in
only 9 ml of elution buffer. For very small cell numbers and single cells, bisulfite
treatment was performed directly on lysed cells (rather than on purified DNA)
by placing the cells in digestion buffer and performing proteinase K digestion
at 50C for 20 min. In both cases, custom-designed methylated and unmethy-
lated oligonucleotides were added at a concentration of 0.1% to serve as
spike-in controls for monitoring bisulfite conversion efficiency. Libraries for
next-generation sequencing were prepared using the EpiGnome Methyl-Seq
kit (Epicenter, EGMK81312) with the following critical steps: bisulfite-con-
verted genomic DNA was transcribed using tagged random hexamer primers,
excess random hexamer primers were digested by the addition of Exonu-
clease I, terminal tagging was performed to extend the synthesized DNA
strand on its 30 side using elongation blocked and tagged random hexamers,
and Illumina-compatible sequencing adapters were introduced through
enrichment PCR using primers corresponding to the tagged sequences flank-
ing the random hexamers. For subsequent library amplification, the number of
PCR cycles was adjusted according to DNA input or cell number, but never ex-
ceeded 18 cycles. The final library was purified twice using Agencourt AMPure
XP beads (Beckman Coulter, A63880). Quality control for the final library was
performed by measuring the DNA concentration with the QuBit dsDNA HS
assay (Life Technologies, Q32851) on QuBit 2.0 Fluorometer (Life Technolo-
gies, Q32866) and by determining library fragment sizes with the Experion
DNA 1K Analysis kit (Bio-Rad, 700-7107) on the Experion Automated Electro-
phoresis Station (Bio-Rad, 701-7000). Sequencing was performed on Illumina
HiSeq 2000 and 2500 machines.
Data Processing
To prepare the bisulfite sequencing reads for downstream analysis, we devel-
oped a bioinformatic pipeline consisting of the following main steps: (1) library
adaptor trimming, (2) bisulfite-aware alignment to the human and mouse ge-
nomes, (3) DNA methylation calling based on the aligned reads, (4) removal
of potential PCR duplicates based on identical start and end positions, (5)
filtering of contaminating reads, and (6) calculation of quality measures. Align-
ment was done with the Bismark Bisulfite Mapper (Krueger and Andrews,
2011), which is a three-letter bisulfite aligner that uses an in silico bisulfite-con-
verted reference genome (Bock, 2012). Library adaptor sequences were
removed with Trimmomatic (Bolger et al., 2014). Furthermore, any reads
containing fewer than three cytosines outside of a CpG context that hadCebeen converted to thymines were discarded, which effectively excluded reads
derived from unconverted and contaminating DNA fragments. DNA methyl-
ation data and summary statistics were extracted from the Bismark methyl-
ation caller output. RnBeads (Assenov et al., 2014) and EpiExplorer (Halachev
et al., 2012) were used in an initial analysis of the data set, and the in-depth
analysis was performed in R (http://www.r-project.org/). All analyses were
done relative to the h19/GRCh37 assembly of the human genome and the
mm10/GRCm38 assembly of the mouse genome.
Confirming Cell Identity
Due to the increased risk of contamination when working with very few cells,
we sought to confirm the cell line identity of the human one-cell and four-cell
experiments. To that end, we retrieved copy-number data for HL60 cells
from the Sanger Cell Lines Project (http://cancer.sanger.ac.uk/cell_lines/
sample/overview?id=905938). From this data set we extracted hg19 region
sets and classified them as deleted, haploid, diploid, or polyploid in HL60 cells.
We then filtered any regions that overlapped with potentially ambiguous re-
gions, which we assembled from curated sets of repeats, microsatellites,
segmental duplications, and self-chain alignments. We repeated this process
for the K562 cell line, using copy-number data from the ENCODE project
(http://hgdownload.cse.ucsc.edu/goldenPath/hg18/encodeDCC/wgEncode
HudsonalphaCnv/wgEncodeHudsonalphaCnvRegionsK562V2.bed.gz). Us-
ing the copy-number annotated region sets for HL60 and K562 cells, we calcu-
lated the average genomic coverage across all region types in each sample
by summing the total bases covered in the regions and then dividing by the
total number of nucleotides. We normalized each sample by dividing by the
coverage in diploid regions for a given cell type.
Saturation Plots and Performance Comparison
We assessed the cumulative CpG coverage of our method by saturation
plots. Starting from a single experiment chosen randomly, we calculated
how many CpGs were covered. We then added additional experiments
randomly and calculated the cumulative number of unique CpGs covered
at each step. We repeated this process ten times and then plotted the
mean CpG coverage against the number of aligned reads. The analysis
was performed separately for human and mouse and for different cell
numbers. We also used the saturation plots to compare our method with
the scRRBS and scPBAT protocols that were published recently (Guo
et al., 2013; Smallwood et al., 2014). To that end, we downloaded published
data from the Sequence Read Archive and the NCBI GEO and included these
data in the saturation analyses (Figures S2 and S3). The analyses were per-
formed separately for CpG islands and non-CpG-island tiling regions in order
to assess the CpG bias of each protocol.
Aggregating DNA Methylation across Region Sets
Changes in DNA methylation tend to affect regulatory regions of the same
type in similar ways (Bock et al., 2012; Feldmann et al., 2013; Stadler
et al., 2011), allowing us to combine DNA methylation measurements across
similar regions to gain statistical power. We assembled sets of biologically
defined regions using public data from several sources. For human, we
pooled three databases: the ENCODE set of transcription factor binding sites
(ENCODE Project Consortium, 2012), the Cistrome database (Liu et al.,
2011), and DNase-hypersensitive regions clustered by tissue specificity
(Sheffield and Furey, 2012; Sheffield et al., 2013). For mouse, we used a
database of region sets that we previously compiled based on ENCODE,
Cistrome, and other public databases (Bock et al., 2012). To quantify DNA
methylation in a given set of genomic regions, we first calculated mean
DNA methylation levels across CpGs for each region individually and then
calculated the mean of these means in the whole region set. We filtered
out small and low-coverage region sets to reduce background noise
(requiring a minimum of 100 and a mean of 200 CpG measurements across
samples in a region set).
Modeling Expected Changes in DNA Methylation
To obtain the control methylation for each region type, we calculated the
average of the summary scores across all untreated samples in a given exper-
iment. Based on the aggregated DNAmethylation values for each region type,ll Reports 10, 1386–1397, March 3, 2015 ª2015 The Authors 1395
we analyzed differences among region types across samples in response to
treatment. For each sample, we normalized the mean DNA methylation of
each region type by subtracting the corresponding control value. When we
plotted the normalized DNA methylation values against the control values,
we observed the expected randomvariation for the control samples (Figure 4B,
top panels), and we observed a negative linear relationship in treated samples
(Figure 4B, red arrows). This linear relationship indicates that regions with high
initial DNA methylation are more likely to undergo a larger reduction in DNA
methylation than regions that are already less methylated in the controls. We
therefore applied linear models to control for the non-informative effect of
initial DNAmethylation values, and also for the impact of CpG density. In a sin-
gle sample, we modeled the difference in mean DNAmethylation for that sam-
ple in comparison to the controls as a linear combination of the control DNA
methylation plus the mean percentage of CpGs across all regions in each
set. By considering the residuals of this linear model, we captured, for each re-
gion set, the change in DNA methylation that is explained neither by the initial
DNA methylation value nor by the CpG content of the region set. These values
are more biologically informative and interpretable than simple differences or
ratios because they are no longer confounded by the effects of initial DNA
methylation values and CpG density.
Inferring Trajectories of Change in the Epigenomic Cell State
Using the region-set analysis outlined above, we sought to place individual
cells on a trajectory defined by the epigenome response to a given treat-
ment. To that end, we selected informative region sets by an unsupervised
data-driven approach as follows: First, we identified region sets that were
consistently differentially methylated in the treatment samples versus the
controls. For each time-series experiment, we used the endpoint samples
as the treatment group (K562: 96-hr azacytidine treatment; HL60: 14-day
vitamin D treatment; mouse ESCs: 120-hr 2i treatment) and the untreated
samples as the control group. We then compared the distribution of resid-
uals in the treatment group versus the controls using t tests performed
separately for each region type. We used a pre-defined p value cutoff
(0.01) to select up to 20 of the top differential region sets. Positive regions
(those that tend to have higher DNA methylation than expected) have signif-
icantly greater residuals in treated than in control samples, whereas nega-
tive region types have significantly lower residuals in treated than in control
samples. We then assigned one summary score for DNA methylation values
above expectation and another summary score for DNA methylation values
below expectation, which we calculated by averaging the scores for each
region set in each category. We used the resulting two scores per sample
as x and y coordinates in the ‘‘lineage plot,’’ which allows us to visualize
where individual samples fall along the treatment-induced trajectory.
Although the construction of the lineage plot is susceptible to some degree
of overfitting for the two extreme points that are used to select the region
sets, it can be validated by assessing whether or not additional time points
or treatments that are not used for model selection are placed in a biolog-
ically meaningful way. This was demonstrated, for example, for the 2i-
based lineage plot that accurately placed the differentiating ESC samples
in the opposite direction of the 2i-induced treatment response.
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